1. A clinical trial compared oral and injectable naltrexone in hospitalized patients with alcohol use disorder.
2. Both forms demonstrated similar reductions in heavy drinking with no statistically significant difference in outcomes.
3. Injectable naltrexone showed higher medication adherence but had substantially higher costs.
4. Phosphatidylethanol levels indicated recent heavy alcohol use in 75.9% of tested participants.
5. Treatment choice for alcohol use disorder may be guided by patient preference, cost, and likelihood of adherence.

Source: JAMA Internal Medicine